Research Archives - Page 2 of 2

UB's Clinical & Translational Research Center Grand Opening

September 18, 2012 by BNMCin Member Institution(s), News, ResearchLeave a Comment

The University at Buffalo‘s (UB) Clinical and Translational Research Center (CTRC) has opened its doors to function as the premier center placing clinicians right next to clinical and translational researchers.
The University at Buffalo School of Medicine and Biomedical Sciences held the grand opening event at the UB-Kaleida Health joint facility located on Ellicott and Goodrich Streets on Thursday, September 20. The CTRC commenced the research collaborations to take place in the immediate future with a ceremony featuring physicians, UB representatives, and city and state officials. Speakers at the event included: Timothy F. Murphy, MD, director of UB’s CTRC and SUNY Distinguished Professor, UB School of Medicine and Biomedical Sciences; Michael E. Cain, MD, UB vice president for health sciences and dean of the UB School of Medicine and Biomedical Sciences; Jeremy M. Jacobs, chairman, UB Council; Satish K. Tripathi, PhD, UB President; Sam Hoyt, Regional President, Empire State Development Corp.; Crystal D. Peoples-Stokes, NYS Assembly; Mark Grisanti, NYS Senate; and Byron W. Brown, mayor, City of Buffalo.

A walk-through of the CTRC and a keynote address by pioneering genomics scientist J. Craig Venter, who was conferred a SUNY honorary doctorate followed the ceremony.

A 170,000 sq. ft. biomedical research facility created to lessen the interval between discovery and cure, the CTRC will allow UB’s physician scientists to do their research upstairs in the CTRC and to see patients and work with clinicians downstairs in the Gates Vascular Institute (GVI).

The CTRC was designed by Cannon Design and constructed by with significant input from UB’s researchers so as to maximize this kind of collaboration in order to catalyze medical breakthroughs and innovative treatments. UB is recruiting more world-class researchers to work within the CTRC; the facility is part of UB’s medical school, which is relocating to downtown Buffalo in 2016 under the UB 2020 plan and with the support of Governor Cuomo’s NYSUNY 2020 legislation. A Biosciences Incubator within UB’s CTRC will assist UB researchers with the commercialization of new medical therapies and technologies.

“The opening of the CTRC is an important step in the relocation of UB’s medical school to the Buffalo Niagara Medical Campus, under the UB 2020 plan and with the support of the NYSUNY 2020 legislation,” said UB President Satish K. Tripathi.

While Kaleida’s GVI occupies the first 4 floors of the facility, the CTRC is housed on floors 5 – 8 with the Jacobs Institute (which will open in October 2012) located on the 5th floor between the two. Read more about the CTRC here.

UB Awarded $1.6M Grant for Students to Study Cybersecurity

September 18, 2012 by BNMCin Member Institution(s), ResearchLeave a Comment

News Release

Cory Nealon

cmnealon@buffalo.edu

716-645-4614

Release Date: September 18, 2012

BUFFALO, N.Y. — The University at Buffalo has received a $1.6 million federal grant to teach students how to protect the United States from cyberattacks.

UB will use the grant, awarded by the National Science Foundation, to bring up to 16 students into its Center of Excellence in Information Systems, Assurance, Research and Education (CEISARE). It is one of wp-contentroximately 50 federally designated centers that supply the United States with graduates trained to protect the nation from computer-based attacks. For more information, visit: http://www.cse.buffalo.edu/caeiae.

The grant will cover the cost of student stipends ($25,000), in-state graduate tuition and fees ($12,000) and books, travel expenses and health insurance ($3,000) for two years. At roughly $80,000 per student, this equals $1.3 million. The remainder of the grant, roughly $345,000, will cover the cost of running the center for five years.

In exchange for the financial support, students must agree to work for the federal government for two years upon graduation. CEISARE Director Shambhu Upadhyaya said students can choose from numerous agencies including the National Security Agency, the Department of Homeland Security, the Department of Defense and the FBI.

“When students graduate with a specialty in cybersecurity, they can basically go wherever they want,” said Upadhyaya, professor of computer science and engineering.

For a picture of Upadhyaya, visit: http://ubphoto.smugmug.com.

An interdisciplinary program, CEISARE includes a varied group of UB faculty. For example, the grant’s co-investigators are: Thomas Cusick, professor of mathematics; H. Raghav Rao, SUNY Distinguished Service Professor in management science and systems department; and Mark Bartholomew, associate professor of law.

The diversity reflects the nuances of computer warfare, which Homeland Security Secretary Janet Napolitano has said is the most serious economic and national security threat that the United States faces. She and other national security officials have warned that electric grids, transportation systems, banks and other industries reliant on computer systems are susceptible to cyberattacks.

Upadhyaya pointed to the 2009 hacking of sensitive information from the Pentagon’s $300 billion, F-35 Joint Strike Fighter project as an example.

The $1.6 million grant is the second multi-year award received by CEISARE. In 2008, it received $860,000 to educate 11 students, some of whom went on to work for the National Security Agency, the Federal Trade Commission and the Office of Inspector General.

Discovery of Essential Genes for Drug-Resistant Bacteria Reveals New, High-Value Drug Targets

September 14, 2012 by BNMCin Member Institution(s), News, ResearchLeave a Comment

Release Date: September 14, 2012Contact: Ellen Goldbaum, goldbaum@buffalo.edu
University at Buffalo
716-645-4605

Discovery of Essential Genes for Drug-Resistant Bacteria Reveals New, High-Value Drug Targets

By studying A. baumannii under “clinically relevant” conditions, the researchers have a more precise understanding of how the bacteria infects humans — and how best to fight it

BUFFALO, N.Y. — Biomedical scientists collaborating on translational research at two Buffalo institutions are reporting the discovery of a novel, and heretofore unrecognized, set of genes essential for the growth of potentially lethal, drug-resistant bacteria. The study not only reveals multiple, new drug targets for this human infection, it also suggests that the typical methods of studying bacteria in rich laboratory media may not be the best way to identify much-needed antimicrobial drug targets.

The paper (http://mbio.asm.org/content/3/4/e00113-12) focuses on a Gram-negative bacteria called A. baumanni. It is published in the current issue of mBio, as an ‘editor’s choice’ paper. The findings may be relevant to other Gram-negative bacteria as well. (A graphic related to the research is at http://www.buffalo.edu/news/13673.)

A. baumannii is responsible for a growing number of hospital-acquired infections around the world. It can be fatal to patients with serious illnesses, the elderly and those who have had surgeries. Infections also have been seen in soldiers returning from Iraq and Afghanistan with battlefield injuries.

“Generally, healthy people don’t get infected,” explains lead author Timothy C. Umland, PhD, research scientist at Hauptman-Woodward Medical Research Institute (HWI) and professor of structural biology in the University at Buffalo School of Medicine and Biomedical Sciences. “But what’s challenging about A. baumannii is that it can survive in the hospital environment and is very hard to eradicate with common disinfectants, leading to healthcare-associated infections.”

Typically, the way that essential genes for microbial pathogens are found is by growing the bacteria under optimal conditions, says co-author Thomas A. Russo, MD, professor in the UB departments of medicine and microbiology and immunology. Genes found to be essential for growth are then entered into the Database of Essential Genes (DEG), which contains genes considered essential for the sustenance of each organism.

The researchers at HWI and UB decided to try to better understand what A. baumannii needs in order to grow when infecting patients.

“Laboratory conditions create a different type of environment from what hwp-contentens in patients,” Umland says, “where certain nutrients the bacteria need will be present in very low amounts and where the bacteria encounter immune and inflammatory responses. We were purposely trying to test for genes that are important for growth in these more realistic environments.”

The team performed a genetic screen designed to identify bacterial genes absolutely required for the growth and survival of A. baumannii in human ascites, a peritoneal fluid that accumulates under a variety of pathologic conditions.

“We found that nearly all of these 18 genes had not been identified as essential in the DEG because they weren’t necessary for growth in an ideal laboratory environment,” explains Russo. “This is a large set of genes that has been flying under the radar.”

He adds: “The biggest concern is that quite a few strains of A. baumannii are resistant to nearly all anti-microbial drugs and some strains are resistant to all of them. To make things worse, there are no new agents being tested for human use in the drug pipeline that are active against A. baumannii. This is a huge problem.”

Not only do the new genes suggest brand new, high-value drug targets for A. baumannii infections, but the genes that have been identified may be relevant to other Gram-negative infections.

“So far, our computational models show that these genes seem to be conserved across Gram-negative infections, meaning that they may lead to new drugs that would be effective for other drug-resistant infections as well,” says Umland.

The researchers who collaborated on the study are now pursuing antibacterial drug discovery efforts focused on the newly identified bacterial targets.

The research was funded by grants from the Telemedicine and Advance Technical Research Center of the U.S. Army Medical Research and Materiel Command, an interdisciplinary grant from UB and a VA Merit Review grant from the U.S. Department of Veterans Affairs.

Other co-authors are: L. Wayne Schultz, PhD, of HWI and UB, and Ulrike MacDonald, Janet M. Beanan and Ruth Olson of the UB Department of Medicine, the Department of Microbiology and Immunology and UB’s Witebsky Center for Microbial Pathogenesis.

Researchers Create Approach to Analyze Genetic Disease Data More Efficiently

September 10, 2012 by BNMCin Campus-wide, Homepage, Member Institution(s), News, ResearchLeave a Comment

Collaborating with the Center for Human Genome Variation at Duke University, Roswell Park Cancer Institute (RPCI) researchers have developed a method to dexterously determine genetic factors that cause disease.
In a recent research study published in The American Journal of Human Genetics, RPCI’s Dr. Qiangian Zhu and fellow researchers have established a computational method called the “preferential linkage disequilibrium” wp-contentroach to isolate causal variants, the genetic irregularities that suggest the presence of a particular disease.

Dr. Zhu is a biostatician who is also the Assistant Member of the Department of Biostatistics and Bioinformatics and the Director of Statistical Genetics and Genomics Resource at RPCI. Her research interests lie in developing statistically sound and computationally efficient methods to find the causal genetic variants of human diseases and traits utilizing high-throughput genetics and genomics data.

Continuing her postdoctoral research after joining RPCI, Dr. Zhu, along with her research collaborators, used variants recorded from genome-wide association studies (GWASs) that analyze people’s DNA to capture genetic variations associated with a disease. The group of researchers cross-referenced variants with a comprehensive variant catalog generated through robust “next generation” sequencing in order to identify the causal variants.

The study examined the DNA from 479 individuals of European descent. “To test our method, we ran it on five diseases for which the causal variants are known, and in every case we did identify the real causal variant,” said Zhu. The group hopes to have the method wp-contentlied to GWASs related to diseases that do not have specific causal variants, resulting in advances towards the development of targeted wp-contentroaches to treating diseases.

Fellow author of the study, David B. Goldstein, Richard and Pat Johnson Distinguished University Professor and Director of the Center for Human Genome Variation at DUMC stated that “This wp-contentroach helps to intergrade the large body of data available in GWASs with the rapidly accumulating sequence data.”

Learn more about the study: Prioritizing Genetic Variants for Causality on the Basis of Preferential Linkage Disequilibrium

At International Cardiology Meeting, UB Chair of Medicine is Honored for Her Distinguished Clinical Research

August 22, 2012 by BNMCin Member Institution(s), News, ResearchLeave a Comment

News Release

At International Cardiology Meeting, UB Chair of Medicine is Honored for Her Distinguished Clinical Research

UB’s Curtis is one of the world’s leading clinical cardiac electrophysiologists and an expert in cardiac arrhythmias.

Contact

Ellen Goldbaum

goldbaum@buffalo.edu

716-645-4605
twitter @egoldbaum

Release Date: August 22, 2012

BUFFALO, N.Y. — Anne B. Curtis, MD, Charles and Mary Bauer Professor and Chair of the Department of Medicine in the University at Buffalo School of Medicine and Biomedical Sciences, has been awarded the Walter Bleifeld Memorial Award for Distinguished Work in Clinical Research. Bleifeld, considered one of the pioneers of modern cardiology, was a professor of medicine and cardiology at the University of Hamburg.

Curtis was presented with the award in July at the 17th World Congress on Heart Disease of the International Academy of Cardiology in Toronto.

The award recognizes Curtis’s outstanding contributions to clinical research. She is one of the world’s leading clinical cardiac electrophysiologists and an expert in cardiac arrhythmias. Her clinical research has significantly advanced knowledge of human cardiac electrophysiology and heart-rhythm abnormalities.

Curtis’s research interests include clinical trials in implantable device therapy for prevention of sudden cardiac death and management of heart failure, as well as clinical trials in atrial fibrillation. She has been principal investigator, co-investigator, sponsor or steering committee member on 85 research studies and clinical trials and has written more than 250 peer-reviewed manuscripts, book chapters, reviews and editorials. She also is author of a book on cardiac pacing.

Curtis received a 2010 Distinguished Fellowship Award from the International Academy of Cardiology.

In 2011, she was a key contributor to guidelines on atrial fibrillation that are issued periodically by the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Earlier this year, she received the 2012 Distinguished Service Award from the Heart Rhythm Society.

She lives in Buffalo.

Palliative Care Program at Roswell Receives Advanced Certification

July 19, 2012 by BNMCin Health care, Homepage, Member Institution(s), Research, WellnessLeave a Comment

Roswell Park Cancer Institute (RCPI) has a strong, dedicated, and experienced team within its Supportive & Palliative Care Program. Most recently, the team received Advanced Certification in Palliative Care for a two-year period from The Joint Commission, an organization that accredits and certifies more than 19,000 health care organizations and programs in the United States.
Palliative Care provides care for individuals with progressive illnesses, helping patients experience relief from symptoms such as pain and the stresses that come with a serious illness. The goal of palliative care is to improve the quality of life for both the patient and the family as well as to work with the other doctors each patient has, providing an extra layer of support. At RPCI, the Supportive & Palliative Care team works with the attending physician and can join the care process at any time, including during curative treatment.

Led by Yashodhara Satchidanand, MD, and Amy Alvarez, MD, the certification makes RPCI the nation’s only dedicated cancer center. It is now also 1 of 15 national hospitals to receive advanced certification to date. “Our team was very excited about receiving the certification. This validates our work and acknowledges that RPCI is known not only for cutting-edge research, but also for compassionate care,” said Dr. Satchidanand, a staff physician and Assistant Professor with the program.

To receive this certification from The Joint Commission, palliative care programs must meet patient-oriented eligibility requirements. The care program must be provided within an accredited hospital, offering a full range of palliative care services to hospitalized patients 24 hours per day, seven days per week. The palliative care team must be easy to contact, readily available to come to the hospital to address patient and family needs when necessary, and must be able to constantly provide the same level of palliative care services around the clock, not just during business hours. Amongst having a minimum number of patients during an initial on-site review, programs must also administer a standardized method of clinical care based on clinical practice guidelines and/or evidence-based practice. To read about more of the eligibility requirements, click here.

“This certification allows us to enhance and help change the perception of palliative care as more than end-of-life care,” notes Dr. Alvarez, a physician with the Department of Supportive & Palliative Care. “It is care for the continuum of the cancer journey, focusing on the goals of the patients and their families.”

Palliative care is wp-contentropriate at any age, at any stage in a serious illness and is designed to meet the patient and family’s psychological, emotional, and physical curative needs.

UB Department of Medicine Names Head of Gastroenterology Division

July 17, 2012 by BNMCin Member Institution(s), News, ResearchLeave a Comment

News Release

UB Department of Medicine Names Head of Gastroenterology Division

Andrew H. Talal, MD, MPH, has been named chief of the Division of Gastroenterology, Hepatology, and Nutrition.Download JPEG

Contact

Sara Saldi

saldi@buffalo.edu

716-645-4593

Release Date: July 17, 2012

BUFFALO, N.Y. — Andrew H. Talal, MD, MPH, associate professor at the Weill Cornell Medical College has been named chief of the Division of Gastroenterology, Hepatology, and Nutrition in the University at Buffalo’s Department of Medicine; he also has been wp-contentointed UB professor of medicine.

The announcement was made by Anne B. Curtis, MD, Charles and Mary Bauer Professor and Chair of the Department of Medicine in UB’s School of Medicine and Biomedical Sciences.

Talal will join UB in September, when Thomas Mahl, MD, clinical professor, who recently served as interim chief, steps down; previously Michael Sitrin, MD, professor, had been leading the division.

Talal has an international reputation for his clinical and translational work in hepatology, the branch of medicine that deals with the liver, gallbladder, biliary tree and pancreas, and management of these disorders. He has been recognized as an authority on viral hepatitis in HIV-infected individuals. A board-certified gastroenterologist and hepatologist, he is a physician-scientist in the Center for the Study of Hepatitis C, a consortium between Rockefeller University, Weill Cornell Medical College and New York Presbyterian Hospital.

His research interests include: the development of biomarkers of the progression and treatment outcomes in hepatitis C virus (HCV) infection; the evaluation of hepatitis C virus-specific immune responses in injection drug users; treatment outcomes in special populations infected with hepatitis C virus (HIV/HCV co-infection, methadone maintenance, patients with bleeding disorders and thalassemia); and novel treatments for hepatitis C.

Talal currently is conducting research funded by such federal agencies as the National Institutes of Health and the Centers for Disease Control on HCV evaluation and treatment among patients in drug treatment programs and risk factors for AIDS among IV drug users.

Talal was the recipient of a Clinton Global Initiatives award from the W.J. Clinton Foundation in 2006, which fostered the development of treatment algorithms for hepatitis viruses B and C.

Talal earned his MD from the University of Texas Health Science Center in San Antonio and received his MPH from the University of North Carolina. He completed his medical residency at the University of Iowa and research and clinical fellowships in gastroenterology at the University of North Carolina.

Before joining the Weill Cornell Medical College, he was a research associate and clinical scholar at the Rockefeller University in New York.

Real-life Spider Men Using Protein Found in Venom to Develop Muscular Dystrophy Treatment

July 16, 2012 by BNMCin Member Institution(s), News, Research, WellnessLeave a Comment

News Release

Real-life Spider Men Using Protein Found in Venom to Develop Muscular Dystrophy Treatment

A grandfather is working with UB scientists in an attempt to save grandson’s life

JB, Jeff Harvey’s grandson. When Harvey discovered JB had Duchenne muscular dystrophy, the grandfather started a company with UB researchers to develop a treatment.

UB researchers Frederick Sachs, Tom Suchyna and Philip Gottlieb are working to develop a treatment for muscular dystrophy using a peptide found in tarantula venom.

UB researchers are developing a treatment for muscular dystrophy using a peptide found in the venom of a Chilean rose tarantula.

Contact

Charlotte Hsu

chsu22@buffalo.edu

716-645-4655

Release Date: July 16, 2012

BUFFALO, N.Y. — While Spider-Man is capturing the imagination of theatergoers, real-life spider men in Upstate New York are working intently to save a young boy’s life.

It all began in 2009, when Jeff Harvey, a stockbroker from the Buffalo suburbs, discovered that his grandson, JB, had Duchenne muscular dystrophy. The disease is fatal. It strikes only boys, causing their muscles to waste away.

Hoping to help his grandson, Harvey searched Google for promising muscular dystrophy treatments and, in a moment of serendipity, stumbled upon University at Buffalo scientist Frederick Sachs, PhD.

Sachs was a professor of physiology and biophysics who had been studying the medical benefits of venom. In the venom of the Chilean rose tarantula, he and his colleagues discovered a protein that held promise for keeping muscular dystrophy at bay. Specifically, the protein helped stop muscle cells from deteriorating.

Within months of getting in touch, Harvey and Sachs co-founded Tonus Therapeutics, a pharmaceutical company devoted to developing the protein as a drug. Though the treatment has yet to be tested in humans, it has helped dystrophic mice gain strength in preliminary experiments.

The therapy is not a cure. But if it works in humans, it could extend the lives of children like JB for years — maybe even decades.

Success can’t come quickly enough.

JB, now four, can’t walk down the stairs alone. When he runs, he waddles. He receives physical therapy and takes steroids as a treatment. While playing tee ball one recent day, he confided to his grandfather, “When I grow up, I want to be a baseball player.”

It was a heartbreaking moment.

“Oh, I would be thrilled if you could be a baseball player,” Harvey remembers replying. He’s doing everything he can to make sure that JB — and other boys like him — can live out their dreams.

For the complete story and multimedia, visit http://www.buffalo.edu/home/feature_story/good-venom.html.

UB Medical School Names Chair of Gynecology and Obstetrics

July 10, 2012 by BNMCin Member Institution(s), News, ResearchLeave a Comment

News Release

UB Medical School Names Chair of Gynecology and Obstetrics

Barnabei has conducted research on postmenopausal women through the Women’s Health Initiative and other federally funded studies

Dr. Barnabei will join UB’s School of Medicine and Biomedical Sciences on Oct. 1.

Download JPEG

Contact

Ellen Goldbaum

goldbaum@buffalo.edu

716-645-4605
twitter @egoldbaum

Release Date: July 10, 2012

BUFFALO, N.Y. — Vanessa M. Barnabei, MD, PhD, the Patrick and Margaret McMahon Endowed Professor of Obstetrics and Gynecology and director of General Obstetrics and Gynecology at The Medical College of Wisconsin in Milwaukee, has been named the

new chair of the Department of Gynecology and Obstetrics at the University at Buffalo School of Medicine and Biomedical Sciences.

Barnabei (pronounced Barnaby), who also will serve as medical director of Women’s Health Services at Kaleida Health, will join UB on October 1.

The hiring of Barnabei brings to eight the number of new chairs recruited by Michael E. Cain, MD, UB vice president for health sciences and dean of the UB medical school, in the past four years. These national hires, Cain says, are a critical piece of his strategic vision for the medical school’s future.

According to Cain, Barnabei rapidly emerged as the top candidate following a comprehensive national search, possessing all the skills needed to advance the UB department and expand its basic and clinical research programs in service of UB’s 2020 strategic goals. Under Barnabei, Cain says, the department will enhance the excellence of its graduate medical education and mentored research training programs. She will help develop and align a comprehensive clinical program at Great Lakes Health, Roswell Park Cancer Institute, and the community.

Barnabei has been an investigator on some of the most important clinical trials examining the effects of hormone therapy on postmenopausal women, including the Women’s Health Initiative, the Heart and Estrogen/Progestin Replacement Study (HERS) and the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. Her research has been supported by the National Institutes of Health, the National Institute for Environmental Health Sciences and industry. Her early research focused on the genetics of the X chromosome as well as perinatal genetics.

Certified by the American Board of Obstetrics and Gynecology, Barnabei also is a certified menopause clinician. She provides obstetrical care in the low-risk setting and manages the gynecological care of women of all ages, with expertise in the care of the midlife woman and vulvar disorders.

Barnabei has held leadership positions at both George Washington University and The Medical College of Wisconsin in areas of women’s health and menopause. In recent years, she has been involved in hospital- and community-based activities aimed at lowering the infant mortality rate in inner-city African American children.

A native of Vineland, New Jersey, Barnabei received her PhD in biology and her MD from the University of Virginia. She did her residency in obstetrics and gynecology at Northwestern University Medical Center in Chicago. She served as an assistant professor and associate professor in the Department of Obstetrics and Gynecology at George Washington University in Washington, DC. In 2010, Barnabei received the Outstanding Faculty Award from The Medical College of Wisconsin. She holds leadership positions in the North American Menopause Society and the Central Association of Obstetricians and Gynecologists.

High School Students Participate in Apprenticeship Program Through Hauptman-Woodward Institute

June 5, 2012 by BNMCin Community, Homepage, Member Institution(s), Outreach, ResearchLeave a Comment

The Hauptman-Woodward Institute (HWI) offers the opportunity for high school students to gain a tremendous experience researching evolution and bioinformatics through the High School Apprenticeship Program. The program is led by Dr. William L. Duax, HWI’s H.A. Hauptman Distinguished Scientist. Dr. Duax is also a biology professor at the University at Buffalo, with a highly extensive research background, especially involving genetic coding. Spinning off of a City Honors School program in place since 2006 that was created to introduce students to medical research, Dr. Duax’s Apprentice Program reached an enrollment peak as 30 students from various schools in Buffalo took a course learning how to use state-of-the-art computer programs heavily used for biological analysis, as well as unique programs developed at HWI.
Since 2006, Dr. Duax has had students spend a great deal of time in his lab, developing their research skills as they unlocked the intricacies of molecular biology through experiments. Not only did the students get to identify research goals and perform the research, they also have been given the opportunity to present their findings at science research fairs. The students can be qualified to be coauthors of abstracts published in national and international leading scientific journals. Many of Dr. Duax’s students have attained scholarships and have gone on to choose career paths involving medical research.

Three levels of participation are available to the students who have gone through the wp-contentlication process, afterward being accepted:

-Students at City Honors Schools can attend the program all day every Friday throughout the school year.

-Students from any Buffalo area school can attend the program one or two afternoons after school throughout the school year

-Students can choose the summer internship option which takes place 5 days a week for up to 12 weeks.

Students from 15 schools in Buffalo worked on projects last summer analyzing proteins. As the program grows in its popularity, the need to accommodate the demand continues to increase. Dr. Duax opened the program to an 8th grader last year, and this year he is expected to have 3 more middle school students participate. The efforts to expose students to the science, technology, engineering and mathematics fields continues to excite interest in students at an early age, increasing their opportunities to become the next generation of doctors and researchers that help advance the medical industry. Applicants are interviewed, given a tour of HWI research facilities, and receive an overview of the goals of the research project, and learn how they will help reach those goals.

Because of the number of wp-contentlicants into the summer program, more than 40 students are expected to participate with the help of donated computers and printers for the summer of 2012 group. As the students learn to wp-contently the learned research skills, present complex research in layman terms to various audiences, and continue to explore ways to break down the genome structure, they also get the opportunity to work in the midst of a cutting-edge Medical Campus full of experts, entrepreneurs, and researchers with a world of knowledge. To-date, there has not been one student who has been turned away from the program. Although increased demand and limited computer resources may change the acceptance standards, the support of donors could change the number of students the program services dramatically. For more information on how to donate resources to enable the program to increase or to find out more about the program, please contact Dr. Duax at 716.898.8616 or duax@hwi.buffalo.edu.

Immco Diagnostics

March 25, 2012 by BNMCin Innovation Center, Life Sciences Companies, ResearchLeave a Comment

Immco Diagnostics develops and distributes autoimmune disease diagnostics and reagents to labs worldwide. Immco offers laboratory testing of autoimmune diseases for the US healthcare market. Its contract research organization supports clinical research trials for pharmaceutical and biotech clients.
Immco assay development led to the first immunofluorescence assay for diagnosing celiac disease and the first Western blot assay for autoimmune hearing loss. The new line of Immco enhanced ELISA assays provides standardized calibration systems, an industry first. Immco is continually expanding its product offering.

Immco’s principal mission is to provide the total solution in autoimmunity™.

Website: www.immcodiagnostics.com

Ceno Technologies

March 25, 2012 by BNMCin Innovation Center, Life Sciences Companies, ResearchLeave a Comment

Ceno Technologies specializes in high-tech particle research, development and production of ultra-fast coated particles. This includes coating and treating microscopic spheres or nanoparticles for use in drug development, personal care and pharmaceutical products.
Ceno’s core technology is the coating of micron and submicron (nano) sized particles with a variety of materials ranging from Metals (Silver, Gold, Palladium, Copper, Zinc, Platinum, Iridium, Nickel, etc.), Alloys and Oxides, Dyes, Organic Materials such as Antibodies and other Bioactive components.

Website: www.cenotechnologies.com